8-K: Lantern Pharma Amends Bylaws Regarding Board of Directors Size

Lantern Pharma's Board of Directors has amended its bylaws to allow the board to set the number of directors within a range of three to nine.

Summary

• Lantern Pharma's Board of Directors approved an amendment to the company's bylaws on May 23, 2024.
• The amendment modifies how the number of directors is determined.
• Previously, the number of directors was set by a majority vote of the directors, assuming no vacancies.
• Now, the number of directors will be set by a resolution of the Board of Directors itself.
• The board size will remain between three and nine directors.

Sentiment

Score: 7

Explanation: The document describes a routine corporate governance change, which is neither particularly positive nor negative. It is a neutral event with a slight positive bias due to the increased flexibility for the board.

Positives

• The amendment provides the Board of Directors with more direct control over its size.
• The change is effective immediately.

Industry Context

Changes to bylaws regarding board composition are common and reflect a company's evolving governance structure. This change provides the board with more direct control over its size.

Comparison to Industry Standards

• Many companies have bylaws that allow the board to determine its size within a specified range.
• This amendment aligns Lantern Pharma with common corporate governance practices.
• Other companies such as Amgen, Gilead, and Regeneron also have similar board size ranges and mechanisms for determining the exact number of directors.

Corporate Governance

Stakeholder Impact

• The change provides the Board of Directors with more direct control over its size, which may indirectly impact shareholders by influencing the board's decision-making process.

Key Dates

Keywords

Board of Directors, Bylaws, Corporate Governance, Director Number, Lantern Pharma